A PHASE I, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF HIV-1 MN RSGP120 AND BIVALENT AIDSVAX B/E (HIV-1 MN RGP120/A244 RGP120) IN COMBINATION WITH QS-21 WITH OR WITHOUT ALUM IN HEALTHY HIV-1 UNINFECTED ADULTS: